Logo
x

Search

Subscribe Now

Exelixis

Exelixis and Sairopa Receive the US FDA’s IND Clearance for ADU-1805 to Treat Advanced Solid Tumors

Exelixis and Sairopa Receive the US FDA’s IND Clearance for ADU-1805 to Treat Advanced Solid Tumors

  • February 14, 2023
Exelixis Entered into a License Agreement with Ajinomoto Co. to Discover and Develop Novel Antibody-Drug Conjugates for Cancer

Exelixis Entered into a License Agreement with Ajinomoto Co. to Discover and Develop Novel Antibody-Drug Conjugates for Cancer

  • January 11, 2023
Exelixis Entered into New License Agreement with Catalent for Three Antibody-Drug Conjugate Programs

Exelixis Entered into New License Agreement with Catalent for Three Antibody-Drug Conjugate Programs

  • November 4, 2022
Exelixis Entered into an Exclusive Clinical Development Collaboration and Option Agreement with Sairopa to Develop ADU-1805 for Cancer

Exelixis Entered into an Exclusive Clinical Development Collaboration and Option Agreement with Sairopa to Develop ADU-1805 for Ca...

  • November 2, 2022
Exelixis Entered into an Exclusive Collaboration Agreement with Cybrexa to Acquire CBX-12 for Solid Tumors

Exelixis Entered into an Exclusive Collaboration Agreement with Cybrexa to Acquire CBX-12 for Solid Tumors

  • November 2, 2022
Exelixis Expands 2021 Clinical Trial Collaboration and Supply Agreement with BMS for XL092 as Fixed Dose Combination in P-Ib (STELLAR-002) Trial for Advanced Solid Tumors

Exelixis Expands 2021 Clinical Trial Collaboration and Supply Agreement with BMS for XL092 as Fixed Dose Combination in P-Ib (STEL...

  • October 5, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.